GlassScriptPhysician profile
Kartheek Ganta
NPI 1235371204
$1,348.78
in general payments reported to CMS, 2019-2025
21 companies · $66.69 in 2025
The $66.69 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $66.46 · 2021: $70.91 · 2022: $91.70 · 2023: $96.21 · 2024: $32.49 · 2025: $66.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.21 | 2021-2023 | |
| Allergan, INC. | $149.29 | 2019-2020 | |
| Ucb, INC. | $140.50 | 2019 | |
| Emd Serono, INC. | $132.57 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $113.96 | 2019-2022 | |
| Amgen INC. | $88.62 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $65.12 | 2020-2021 | |
| Lundbeck LLC | $63.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $54.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.65 | 2025 | Wainua |
| Lilly USA, LLC | $50.13 | 2019 | |
| Akcea Therapeutics, INC. | $49.61 | 2019 | |
| Csl Behring | $37.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $35.79 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $22.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.42 | 2019 | |
| Biogen, INC. | $19.19 | 2019 | |
| Eisai INC. | $18.62 | 2019 | |
| Pfizer INC. | $16.04 | 2025 | |
| Grifols USA, LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kartheek Ganta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.